Skip to main content
Caplight Logo









BriSTAR Immunotech

BriSTAR Immunotech

Private
BeijingHealthcare & Life Scienceshttps://www.bristarimmunotech.com/

Last Round

Series C

Jul 6, 2026

Total Funding Raised

$65.5M

Company Overview

BriSTAR Immunotech is a clinical-stage biotechnology company that develops engineered T-cell immunotherapy products for cancer and autoimmune diseases using its proprietary STAR-T and enTCR-T technology platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

cell therapyT-cell immunotherapyCAR-TSTAR-TT-cell receptor therapyenTCR-Tbiotechnologydrug discoveryprecision medicinenext-gen immunotherapyin vivo cell engineeringcancer immunotherapyAI-driven drug discoverybiotech R&Dclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BriSTAR Immunotech Comparables

Compare BriSTAR Immunotech with similar companies based on industry and business-model similarity.

BriSTAR Immunotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IASO Bio
81%
BioSyngen
81%
AstraZeneca
81%

BriSTAR Immunotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 6, 2026
Series B ExtensionJul 18, 2022
Series BOct 11, 2021
Series A ExtensionJan 1, 2020

BriSTAR Immunotech Investors

Notable investors and investment history

BriSTAR Immunotech investors
InvestorRounds
Beijing Chang DevelopmentSeries B
Loyal Valley CapitalSeries C
Shenzhen Sangel Venture CapitalSeries B
Highlight CapitalSeries B
Daoyuan CapitalSeries B
Qifu CapitalSeries A, Angel, Pre Seed
Hankang CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2022

    Completed a Series B Extension round of funding.

  • Oct 11, 2021

    $31M round led by 华创资本

BriSTAR Immunotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BriSTAR Immunotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BriSTAR Immunotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range8
Year Founded2018
Last FundingJul 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?